Bristol-Myers Squibb Co.'s latest data for the combination of Opdivo and Yervoy suggest a role for the duo in a new indication for small cell lung cancer (SCLC) and generally give more support to the emerging biomarker of "tumor mutation burden" in guiding immunotherapy treatment.
PD-L1 expression has been the most commonly used biomarker for checkpoint inhibitor immunotherapies to date, but is a flawed measure...